Rosiglitazone and Heart Failure: The Controversy and Clinical Implications
| Autor: | Rubinder S. Ruby, David Tepper, Imran S. Virk |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Myocardial Infarction MEDLINE Emergency Nursing Risk Assessment Rosiglitazone Risk Factors medicine Humans Hypoglycemic Agents Intensive care medicine Heart Failure business.industry Middle Aged medicine.disease Viewpoints United States Diabetes Mellitus Type 2 Heart failure Emergency Medicine Female Thiazolidinediones Medical emergency Cardiology and Cardiovascular Medicine Risk assessment business medicine.drug |
| Zdroj: | Congestive Heart Failure. 13:293-295 |
| ISSN: | 1751-7133 1527-5299 |
| DOI: | 10.1111/j.1527-5299.2007.06241.x |
| Popis: | In this issue of Congestive Heart Failure, the editor of this department addresses a topic on which there is conflicting data. Dr Tepper selected 2 of the most relevant abstracts for review. His comments on the conflicting data-and the polarized viewpoints among physicians that often result-provide insights on the clinical implications of the controversy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text